---
title: "Double Medical released its 2024 annual performance, with a net profit attributable to the parent company of 357 million yuan, a year-on-year increase of 505.16%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237209919.md"
description: "Double Medical released its 2024 annual report, with operating revenue of 2.136 billion yuan, a year-on-year increase of 39.29%; net profit attributable to shareholders of the parent company was 357 million yuan, a year-on-year increase of 505.16%; net profit excluding non-recurring gains and losses was 285 million yuan, a year-on-year increase of 2603.93%. The basic earnings per share were 0.86 yuan, and it plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-23T14:46:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237209919.md)
  - [en](https://longbridge.com/en/news/237209919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237209919.md)
generator: "portal-rs"
---

# Double Medical released its 2024 annual performance, with a net profit attributable to the parent company of 357 million yuan, a year-on-year increase of 505.16%

According to the Zhitong Finance APP, Double Medical (002901.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 2.136 billion yuan, a year-on-year increase of 39.29%. The net profit attributable to shareholders of the listed company was 357 million yuan, a year-on-year increase of 505.16%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 285 million yuan, a year-on-year increase of 2603.93%. The basic earnings per share were 0.86 yuan. It is proposed to distribute a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [002901.CN](https://longbridge.com/en/quote/002901.CN.md)

## Related News & Research

- [Viromed Medical’s Heike Perbandt, closely associated with managing body member Uwe Perbandt, sells shares for EUR 52,000](https://longbridge.com/en/news/298227013.md)
- [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/298045178.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [Eurofins Scientific CEO-controlled Analytical Bioventures buys EUR 218,458 of shares](https://longbridge.com/en/news/298342552.md)
- [03:00 ETRibbon Bio Appoints Jay Therrien as Chief Business Officer](https://longbridge.com/en/news/298274904.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**